看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
' N9 K& Z* h: v: y
9 \! O4 Y5 F2 U! R- V
; [0 z1 v( g! K0 k! j! f( |* mCurrently available feasibility data for possible combination strategies.
# e, R) `3 a3 m- ~6 _) C. i————————————————————————————————. |- K" h- Y( s3 o* r1 A6 n' R
Combination Feasibility according to preliminary data
0 P6 L. x% m- } ~5 H) u7 Q——————————————————————————————————
) J$ Y# R# q @Bevacizumab + sorafenib Yes, reduced dose
4 L+ ?3 s, q/ M1 FBevacizumab + sunitinib† No 8 P N3 x; k: Z1 b
Bevacizumab + temsirolimus Yes 5 w- D% e- R, T8 W+ @
Bevacizumab + everolimus Yes 9 F* @) G6 n% `+ w g! r' e
Sorafenib + sunitinib ?
1 X& I+ h& g$ l. j Y: ~: x: z% _Sorafenib + temsirolimus Yes, reduced dose + E6 T* c y9 u2 Q8 A: j" m% ?
Sorafenib + everolimus Yes, reduced dose 5 h% P2 Q/ [. c% y2 e0 O
Sunitinib + temsirolimus† No
* E3 w; n- \4 }) w2 ^" wSunitinib + everolimus ?
* v) ]3 v% _. g9 @- PTemsirolimus + everolimus ?
7 T& Y! a" p0 l7 ]————————————————————% F- I+ A5 B! Z6 F
†Led to US FDA warning.
- P2 y9 W8 T0 x! c?: As yet unattempted combination.& n. m8 e) {0 d
|
显身卡
3 s! J \6 Y* B) D
